Takeda Bets on Fate Therapeutics

Xconomy San Diego — 

Japan-based Takeda Pharmaceutical said it has made an equity investment in San Diego-based Fate Therapeutics, the developer of stem cell technology. The amount wasn’t disclosed, but the announcement comes a few weeks after Fate disclosed in regulatory filings that it has increased the size of its current equity financing to $36 million, and pulled in another $1 million in debt financing. Takeda Ventures joins a syndicate of investors behind Fate, which includes Arch Venture Partners, OVP Venture Partners, Venrock, Polaris Venture Partners, Astellas Venture Management, Genzyme Ventures, and a third unnamed corporate venture investment group.